Tiziana Life Sciences has four submissions accepted to virtual ASCO event

Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) has said it will showcase data via four submissions at the virtual replacement for the world’s leading cancer conference. Leading the way are two poster sessions on StemPrintER at the American Society of Clinical Oncology (ASCO) summit. The technology is being developed to predict the potential recurrence of breast cancer. In one of those posters, there is a direct comparison of Tiziana's product with current market leader, Oncotype DX. A further two ‘e-abstracts’ assess the potential of the firm’s Milciclib drug candidate in treating hepatocellular carcinoma. "These data being presented at ASCO are significant for our oncology portfolio and highlight a complementary technology for detection of breast cancer," Dr Kunwar Shailubhai, chief executive and chief scientific officer of Tiziana said in a statement. "Of particular note is that one of these studies was selected to be part of a poster discussion session during the meeting.  “We look forward to sharing these critical data on our StemPrintER clinical diagnostic for ER+/HER2- breast cancer patients and its utility in potentially optimizing therapeutic decision-making, especially in the discussion of StemPrintER relative to the current market leader, Oncotype DX," he added. The information will be available from May 13 onwards, while the ASCO conference itself, which attracts the cream of the industry, runs from May 29-31. Below are the details of the submissions: Poster discussion sessions Abstract #1020: "Comparison of StemPrintER, a novel biology-based genomic predictor of distant recurrence in breast cancer, with Oncotype DX in the TransATAC cohort" Abstract #1057: "Integration of the stem cell biology-based genomic tool, StemPrintER, with clinicopathological parameters for the prediction of distant recurrence in ER+/HER2- breast cancer (BC) patients" e-abstracts e16711: "Phase 2a safety and efficacy of Milciclib, a pan-cyclin dependent kinase inhibitor, in unresectable, sorafenib-refractory or -intolerant hepatocellular carcinoma patients" e16634: "Safety and clinical activity of combination treatment with regorafenib and milciclib in liver transplant patients with hepatocellular carcinoma recurrence